Our verdict is Uncertain significance. Variant got 5 ACMG points: 5P and 0B. PM2PP2PP3_Moderate
The NM_001161352.2(KCNMA1):c.1181G>A(p.Arg394His) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,676 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
KCNMA1 (HGNC:6284): (potassium calcium-activated channel subfamily M alpha 1) This gene encodes the alpha subunit of calcium-activated BK channel. The encoded protein is involved in several physiological processes including smooth muscle contraction, neurotransmitter release and neuronal excitability. Mutations in this gene are associated with a spectrum of neurological disorders including Paroxysmal Nonkinesigenic Dyskinesia 3, Idiopathic Generalized Epilepsy 16 and Liang-Wang syndrome. [provided by RefSeq, Aug 2022]
Verdict is Uncertain_significance. Variant got 5 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP2
Missense variant in the KCNMA1 gene, where missense mutations are typically associated with disease (based on misZ statistic). The gene has 12 curated pathogenic missense variants (we use a threshold of 10). The gene has 25 curated benign missense variants. Gene score misZ: 5.0622 (above the threshold of 3.09). Trascript score misZ: 6.5162 (above the threshold of 3.09). GenCC associations: The gene is linked to cerebellar atrophy, developmental delay, and seizures, generalized epilepsy-paroxysmal dyskinesia syndrome, Liang-Wang syndrome.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.865
Review Status: criteria provided, single submitter
Collection Method: clinical testing
In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt KCNMA1 protein function. ClinVar contains an entry for this variant (Variation ID: 532942). This variant has not been reported in the literature in individuals affected with KCNMA1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 394 of the KCNMA1 protein (p.Arg394His). -
not provided Uncertain:1
Mar 16, 2022
GeneDx
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing
Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -
.;Gain of ubiquitination at K395 (P = 0.0619);Gain of ubiquitination at K395 (P = 0.0619);Gain of ubiquitination at K395 (P = 0.0619);.;Gain of ubiquitination at K395 (P = 0.0619);.;Gain of ubiquitination at K395 (P = 0.0619);Gain of ubiquitination at K395 (P = 0.0619);Gain of ubiquitination at K395 (P = 0.0619);Gain of ubiquitination at K395 (P = 0.0619);Gain of ubiquitination at K395 (P = 0.0619);Gain of ubiquitination at K395 (P = 0.0619);.;.;Gain of ubiquitination at K395 (P = 0.0619);Gain of ubiquitination at K395 (P = 0.0619);Gain of ubiquitination at K395 (P = 0.0619);Gain of ubiquitination at K395 (P = 0.0619);Gain of ubiquitination at K395 (P = 0.0619);Gain of ubiquitination at K395 (P = 0.0619);.;.;.;.;.;.;Gain of ubiquitination at K395 (P = 0.0619);.;Gain of ubiquitination at K395 (P = 0.0619);Gain of ubiquitination at K395 (P = 0.0619);Gain of ubiquitination at K395 (P = 0.0619);.;.;.;Gain of ubiquitination at K395 (P = 0.0619);.;Gain of ubiquitination at K395 (P = 0.0619);Gain of ubiquitination at K395 (P = 0.0619);.;Gain of ubiquitination at K395 (P = 0.0619);Gain of ubiquitination at K395 (P = 0.0619);Gain of ubiquitination at K395 (P = 0.0619);.;.;Gain of ubiquitination at K395 (P = 0.0619);